Nacho Aguilo from our research partner University of Zaragoza has been selected as the inaugural recipient of the CTVD Early Career Scientist Award for his contributions to research in TB host-pathogen biology, immunology, and vaccinology. CTVD is the Collaboration for TB Vaccine Discovery, and is funded by the Bill & Melinda Gates Foundation.
The a award was based on his contribution to the characterization of MTBVAC vaccine candidate and studied the mechanisms of virulence of M. tuberculosis and pulmonary vaccination which contributed to the 14 TB-related publications you have to date. “Early career scientists are essential to ensure that the field remains innovative and scientifically robust,” according to the CTVD.
Over the years, Dr Nacho Aguilo has made significant contributions to research in TB host-pathogen biology, immunology, and vaccinology. His main research activities are related in the host pathogen in Mycobacterium tuberculosis, studying the mechanisms of virulence of M. tuberculosis and pulmonary vaccination. Dr Aguilo has been working in the study of apoptosis induction as a key mechanism of virulence of M. tuberculosis, mediated by ESAT-6. Dr Aguilo has contributed to the characterization of MTBVAC vaccine candidate and demonstrated the safety and efficacy of MTBVAC in a mice neonatal model.